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May 7, 2013:1929–34as low-density lipoprotein cholesterol (LDL-C) and the risk of
disease within the context of a Mendelian randomization study can
be complex. Indeed, it was initially unclear whether the much-
larger-than-expected reduced risk of coronary heart disease
(CHD) reported in the original PCSK9 studies was caused by the
effect of lifelong exposure to lower LDL-C or to the combination
of lower LDL-C and other pleiotropic effects mediated by this
polymorphism (1). For this reason, we specifically sought to
evaluate the association between lifelong exposure to lower
LDL-C and the risk of CHD mediated by polymorphism in a
variety of different genes, each of which presumably affects circu-
lating LDL-C levels by a different mechanism or biological
pathway.
We found that each polymorphism included in our study was
associated with a highly consistent effect on the risk of CHD when
measured per unit lower of LDL-C with no evidence for hetero-
geneity of effect (2). In addition, we found an essentially identical
magnitude of effect when we estimated the association between
lifelong exposure to lower LDL-C and the risk of CHD by using
a genetic LDL-C score, which measures the effect of lifelong
exposure to lower LDL-C mediated by the combined effect of the
included polymorphism. The practice of combining multiple
instruments for a modifiable exposure into a single instrument to
estimate the magnitude of a causal effect is common in the field of
econometrics (3). Indeed, the magnitude of the association be-
tween lifetime exposure to lower LDL-C and the risk of CHD
observed in our study has now been independently confirmed using
separate genetic LDL-C scores composed of different combina-
tions of polymorphism in two other studies (4,5).
The repeated replication of the same magnitude of effect per
unit of lower LDL-C for each individual polymorphism included
in our study, and for multiple different genetic LDL-C scores
measured in different populations, strongly argues that our esti-
mate of the magnitude of the effect of lifelong exposure to lower
LDL-C on the risk of CHD is unlikely to be confounded by
population stratification, linkage disequilibrium, pleiotropy, or
other systematic bias, such as attenuation of effect with age as
suggested by Dr. Schooling and colleagues because it would be
implausible that each of these associations was affected by 1 or
more of these biases in the same direction with the same magni-
tude of effect. Furthermore, in multiple metaregression analyses,
we found no evidence for effect modification of age on the
association between circulating LDL-C levels and any of the
polymorphism included in our study (including rs646776). There-
fore, we believe that it is very unlikely that the results of our study
were inflated by the potential attenuation of LDL-C genetic
associations with age as suggested by Schooling et al. Instead, we
believe that the results of our study, and those of other studies,
provide robust naturally randomized evidence for the magnitude of
the association between lifelong exposure to lower LDL-C and the
risk of CHD.
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How to Balance Cardiometabolic
Benefits and Risks of Statins
The paper by Waters et al. (1) is timely and important in
delineating overall risk-benefit profiles of statin therapy in
patients with risk factors for diabetes. However, this study
reminds physicians of the important issue of risk-benefit con-
cept in treating patients with drugs. Therefore, it is important
to look over the hazard ratio (HR) of new onset diabetes
(NOD) and cardiovascular events (CVE) in patients by lower
dose (atorvastatin 10 mg or simvastatin 20 to 40 mg) versus
higher dose (atorvastatin 80 mg) statin therapy according to the
number of NOD risk factors: fasting blood glucose 100 mg/dl,
fasting triglycerides 150 mg/dl, body mass index 30 kg/m2, and
istory of hypertension. In Figure 1 of Waters et al. (1), in risk
actor 0, HRs of NOD and CVE are 0.96 and 0.95 by lower dose
ersus higher dose statin therapy; in risk factor 1, HRs of NOD
nd CVE are 0.97 and 0.82 by lower dose versus higher dose statin
herapy; in risk factor 2, HRs of NOD and CVE are 1.15 and 0.85
y lower dose versus higher dose statin therapy; in risk factor 3,
Rs of NOD and CVE are 1.31 and 0.82 by lower dose versus
igher dose statin therapy; in risk factor 4, HRs of NOD and CVE
re 1.36 and 0.65 by lower dose versus higher dose statin therapy;
nd overall, HRs of NOD and CVE are 1.16 and 0.85 by lower
ose versus higher dose statin therapy, respectively (1). Therefore,
t is true that higher dose statin therapy significantly reduced CVE;
owever, when both HRs are considered simultaneously, it seems
hat higher dose statin therapy does not have any benefit compared
ith lower dose statin therapy.
Consistent with this observation, recent clinical and meta-
nalysis studies have demonstrated that the effect of statins to
nduce type 2 diabetes is dose-dependent (2,3). Hypercholes-
erolemic patients receiving high dose atorvastatin (80 mg)
eveloped greater insulin resistance, higher fasting insulin
evels, and higher HbA1c levels when compared with patients
eceiving the low-dose atorvastatin (10 mg) or placebo, sug-
esting that high-dose statin therapy may have greater adverse
ffects on glucose homeostasis than low-dose therapy (2). A
ecent meta-analysis demonstrated that intensive-dose statins
ncreased the risk of developing type 2 diabetes by 1.12 (95%
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May 7, 2013:1929–34confidence interval: 1.04 to 1.22) despite of reducing the risk of
cardiovascular events by 0.84 (95% confidence interval: 0.75 to
0.94), compared with moderate-dose statins (3). I speculate that
long-term adverse effects of NOD may generate a relative
increase in deaths. Indeed, a recent large-scale randomized
clinical trial confirms my speculation. In individuals with 1 or
more risk factors for diabetes, statin was associated with a 39%
reduction in the primary endpoint, but in individuals with no
major diabetes risk factors, statin was associated with a 52%
reduction in the primary endpoint (4). One should consider that
higher dose statin therapy may cause more adverse effects and
therefore lead to differences in routine clinical care between
those treated with higher and lower dose regimens. Thus, it is
important to consider the cardiovascular and metabolic context
and natural history of diseases when choosing statin therapy for
optimal individual patient health over the long term (5).
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Statin Treatment and Diabetes
Waters et al. (1) discuss further evidence relating to increased
incidence of new diabetes with statins. Superficially, the message from
these and other studies is reassuring: statins have transformed the
management of atherosclerotic disease; intensive therapy shows
greater benefit than “standard” therapy; the rate of incident diabetes
with statins is relatively small; benefits of statins are still apparent in
patients with diabetes. It is further reassuring from this study (using data
from the TNT [Treating to New Targets] and IDEAL [Incremental
Decrease in Endpoints through Aggressive Lipid-lowering] studies) that
those who develop diabetes are those who appear to be at risk.
The authors imply, but do not state, that all 4 risk factors for
diabetes considered were equally important, and that there was nodifference in incident diabetes between those with no or 1 risk factor.
It is surprising that age was not considered as a factor in their analysis.
Recent analyses of data from major lipid trials have documented the
incidence of diabetes based on fasting glucose, but postprandial data
are not available. The rate of incident diabetes may thus be underes-
timated. The effect of statins on diabetes incidence may also be
underestimated because many of the patients in lipid trials have
already been exposed to statins prior to the trial. Also, the comparators
in the TNT and IDEAL studies (10 mg atorvastatin or 20 mg
simvastatin) may themselves increase incident diabetes, thus partially
masking the influence of intensive therapy.
It is unlikely that statins cause diabetes, but rather exacerbate a
pre-existing dysglycemic state. Their impact almost certainly goes
beyond the reported annual 2% increase in new diabetes. In the
TNT and IDEAL studies, around 17% of patients had diabetes at
baseline (previously diagnosed or increased fasting plasma glucose
[FPG]). Deterioration in glycemic control in diabetic patients
using statins is well documented (2) but has not been as extensively
studied as the increase in incident diabetes. The increase in HbA1c
with statins is similar in magnitude to the decrease seen with the
newer classes of oral hypoglycemic agents. The mechanism is not
known. Impaired -cell function may well be involved (2), but
mpaired insulin sensitivity has also been documented (3). If
mpaired insulin secretion is the predominant mechanism, then
ncreased FPG may be the earliest diagnostic criterion for diabetes
o be satisfied. If the problem is impaired insulin sensitivity, then
ncreased postprandial glucose may appear first. Postprandial
nsulin and lipid excursions are well known to contribute to
rogression of macrovascular disease.
Development of diabetes or worsening of its control has the
otential to impair quality of life through increased need for
reatment, increased clinic visits, side effects of treatment, and
evelopment of complications. These considerations are not minor
ut we should certainly not deny patients the considerable benefits
f statins where they are indicated. Statins can be lifesaving, but it
s noteworthy that intensive statin therapy was not associated with
ecreased overall or cardiovascular mortality in either the TNT or
DEAL studies. Careful consideration of the risks and benefits are
eeded in each case, and we need greater understanding of the
iffering effects of class members on glucose homeostasis.
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